$TELA
TELA Bio, Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024015050 Filed on November 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $18.96M
YoY Change 25.94%
Cost Of Revenue $6.099M
YoY Change 30.88%
Gross Profit $12.86M
YoY Change 23.77%
Gross Profit Margin 67.83%
Selling, General & Admin $20.16M
YoY Change 10.73%
% of Gross Profit 156.75%
Research & Development $2.068M
YoY Change -12.67%
% of Gross Profit 16.08%
Depreciation & Amortization $263.0K
YoY Change 19.55%
% of Gross Profit 2.05%
Operating Expenses $22.22M
YoY Change 8.04%
Operating Profit -$9.365M
YoY Change -8.01%
Interest Expense -$1.344M
YoY Change -200.75%
% of Operating Profit
Other Income/Expense, Net -$1.007M
YoY Change 29.77%
Pretax Income -$10.37M
YoY Change -5.36%
Income Tax
% Of Pretax Income
Net Earnings -$10.37M
YoY Change -5.34%
Net Earnings / Revenue -54.71%
Basic Earnings Per Share -$0.42
Diluted Earnings Per Share -$0.42
COMMON SHARES
Basic Shares Outstanding 39.39M 24.71M
Diluted Shares Outstanding 24.70M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.30M
YoY Change -70.27%
Cash & Equivalents $17.30M
Short-Term Investments
Other Short-Term Assets $2.009M
YoY Change 21.02%
Inventory $13.60M
Prepaid Expenses
Receivables $11.22M
Other Receivables $0.00
Total Short-Term Assets $44.13M
YoY Change -46.35%
LONG-TERM ASSETS
Property, Plant & Equipment $2.423M
YoY Change 38.54%
Goodwill
YoY Change
Intangibles $1.834M
YoY Change -17.16%
Long-Term Investments
YoY Change
Other Assets $2.566M
YoY Change
Total Long-Term Assets $8.884M
YoY Change 75.4%
TOTAL ASSETS
Total Short-Term Assets $44.13M
Total Long-Term Assets $8.884M
Total Assets $53.02M
YoY Change -39.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.479M
YoY Change -19.8%
Accrued Expenses $14.38M
YoY Change 17.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.86M
YoY Change 9.94%
LONG-TERM LIABILITIES
Long-Term Debt $40.97M
YoY Change 1.5%
Other Long-Term Liabilities $1.460M
YoY Change 36.7%
Total Long-Term Liabilities $42.43M
YoY Change 2.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.86M
Total Long-Term Liabilities $42.43M
Total Liabilities $59.29M
YoY Change 4.44%
SHAREHOLDERS EQUITY
Retained Earnings -$349.5M
YoY Change 13.47%
Common Stock $25.00K
YoY Change 4.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.272M
YoY Change
Total Liabilities & Shareholders Equity $53.02M
YoY Change -39.28%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$10.37M
YoY Change -5.34%
Depreciation, Depletion And Amortization $263.0K
YoY Change 19.55%
Cash From Operating Activities -$8.983M
YoY Change 28.88%
INVESTING ACTIVITIES
Capital Expenditures $122.0K
YoY Change -12.86%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$122.0K
YoY Change -12.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 98.00K
YoY Change 22.5%
NET CHANGE
Cash From Operating Activities -8.983M
Cash From Investing Activities -122.0K
Cash From Financing Activities 98.00K
Net Change In Cash -9.007M
YoY Change 28.12%
FREE CASH FLOW
Cash From Operating Activities -$8.983M
Capital Expenditures $122.0K
Free Cash Flow -$9.105M
YoY Change 28.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24717193
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24494675
dei Entity Central Index Key
EntityCentralIndexKey
0001561921
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
tela Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
0
tela Class Of Warrant Or Right Cancelled
ClassOfWarrantOrRightCancelled
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39130
dei Entity Registrant Name
EntityRegistrantName
TELA Bio, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5320061
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Great Valley Parkway, Suite 24
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
320-2930
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
TELA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39388443
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17301000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46729000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
230000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
416000
CY2024Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
11222000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
9737000
CY2024Q3 us-gaap Inventory Net
InventoryNet
13600000
CY2023Q4 us-gaap Inventory Net
InventoryNet
13162000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2009000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2098000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
44132000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
71726000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2423000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1984000
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1834000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2119000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1796000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1954000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2566000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
265000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
265000
CY2024Q3 us-gaap Assets
Assets
53016000
CY2023Q4 us-gaap Assets
Assets
78048000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2479000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1667000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14379000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15300000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
16858000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16967000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40970000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40515000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1460000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1685000
CY2024Q3 us-gaap Liabilities
Liabilities
59288000
CY2023Q4 us-gaap Liabilities
Liabilities
59167000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24717193
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24494675
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
25000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
343076000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
339655000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
149000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
91000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349522000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-320889000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6272000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18881000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53016000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78048000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18957000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15052000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51651000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41455000
CY2024Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
6004000
CY2023Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
4568000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
16099000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
12682000
CY2024Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
95000
CY2023Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
95000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
285000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
285000
CY2024Q3 us-gaap Gross Profit
GrossProfit
12858000
CY2023Q3 us-gaap Gross Profit
GrossProfit
10389000
us-gaap Gross Profit
GrossProfit
35267000
us-gaap Gross Profit
GrossProfit
28488000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16472000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14474000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
50691000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
42517000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3683000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3728000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11133000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10834000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2068000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2368000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6784000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6934000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
22223000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
20570000
us-gaap Operating Expenses
OperatingExpenses
68608000
us-gaap Operating Expenses
OperatingExpenses
60285000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
7580000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9365000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10181000
us-gaap Operating Income Loss
OperatingIncomeLoss
-25761000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31797000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1344000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1334000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
4007000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3878000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
337000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
558000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1135000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1901000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1007000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-776000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2872000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1977000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10372000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10957000
us-gaap Net Income Loss
NetIncomeLoss
-28633000
us-gaap Net Income Loss
NetIncomeLoss
-33774000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24703578
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24703578
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24483664
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24483664
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24648933
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24648933
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22322256
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22322256
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10372000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10957000
us-gaap Net Income Loss
NetIncomeLoss
-28633000
us-gaap Net Income Loss
NetIncomeLoss
-33774000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
51000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
51000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
58000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10321000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10906000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28575000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33789000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2870000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
117000
CY2024Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
19000
CY2024Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
51000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1081000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-10372000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6272000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18881000
tela Apic Share Based Payment Arrangement Vesting Of Restricted Stock Units And Exercise Of Stock Options
ApicShareBasedPaymentArrangementVestingOfRestrictedStockUnitsAndExerciseOfStockOptions
226000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
281000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
358000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
58000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3273000
us-gaap Net Income Loss
NetIncomeLoss
-28633000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-6272000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40005000
CY2023Q3 tela Apic Share Based Payment Arrangement Vesting Of Restricted Stock Units And Exercise Of Stock Options
ApicShareBasedPaymentArrangementVestingOfRestrictedStockUnitsAndExerciseOfStockOptions
1000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
88000
CY2023Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5000
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
51000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1369000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10957000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
30552000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14305000
tela Apic Share Based Payment Arrangement Vesting Of Restricted Stock Units And Exercise Of Stock Options
ApicShareBasedPaymentArrangementVestingOfRestrictedStockUnitsAndExerciseOfStockOptions
101000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
88000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
285000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3791000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46341000
us-gaap Net Income Loss
NetIncomeLoss
-33774000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
30552000
us-gaap Profit Loss
ProfitLoss
-28633000
us-gaap Profit Loss
ProfitLoss
-33774000
us-gaap Depreciation
Depreciation
461000
us-gaap Depreciation
Depreciation
362000
us-gaap Paid In Kind Interest
PaidInKindInterest
455000
us-gaap Paid In Kind Interest
PaidInKindInterest
447000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
285000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
285000
tela Net Changes In Operating Lease Right Of Use Assets And Liabilities
NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities
73000
tela Net Changes In Operating Lease Right Of Use Assets And Liabilities
NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities
33000
us-gaap Inventory Write Down
InventoryWriteDown
1563000
us-gaap Inventory Write Down
InventoryWriteDown
992000
us-gaap Share Based Compensation
ShareBasedCompensation
3273000
us-gaap Share Based Compensation
ShareBasedCompensation
3791000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
7580000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1745000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1456000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2356000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3503000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-524000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-361000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
636000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1535000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-967000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1373000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-93000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
186000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34064000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29806000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
725000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
406000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
5366000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4641000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-406000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46341000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
226000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
101000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
358000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
285000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
281000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
88000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
149000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46245000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-154000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
150000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29428000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16183000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46994000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42019000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17566000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58202000
us-gaap Interest Paid Net
InterestPaidNet
3552000
us-gaap Interest Paid Net
InterestPaidNet
3431000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
175000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
23000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-349500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company’s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates.</p>
tela Incremental Costs Of Obtaining Contract
IncrementalCostsOfObtainingContract
0
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18957000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15052000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51651000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41455000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3188857
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3155247
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7854000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9216000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2828000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2828000
CY2024Q3 tela Accrued Expenses Amount Due To Contract Manufacturer
AccruedExpensesAmountDueToContractManufacturer
2314000
CY2023Q4 tela Accrued Expenses Amount Due To Contract Manufacturer
AccruedExpensesAmountDueToContractManufacturer
2024000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
559000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
565000
CY2024Q3 tela Research And Development Expenses Payable Current
ResearchAndDevelopmentExpensesPayableCurrent
16000
CY2023Q4 tela Research And Development Expenses Payable Current
ResearchAndDevelopmentExpensesPayableCurrent
140000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
808000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
527000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14379000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15300000
CY2024Q3 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
2000000
CY2023Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
2000000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1030000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1485000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
40970000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
40515000
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
88556
tela Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
0
CY2024Q3 tela Equity Incentive Plans Number
EquityIncentivePlansNumber
2
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1081000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1369000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3273000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3791000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2162453
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
259900
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.86
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
38431
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
255060
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.35
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2128862
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.91
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M13D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2099563
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.94
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y29D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1612281
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.732
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0429
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M20D
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-015050-index-headers.html Edgar Link pending
0001558370-24-015050-index.html Edgar Link pending
0001558370-24-015050.txt Edgar Link pending
0001558370-24-015050-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tela-20240930.xsd Edgar Link pending
tela-20240930x10q.htm Edgar Link pending
tela-20240930xex10d1.htm Edgar Link pending
tela-20240930xex31d1.htm Edgar Link pending
tela-20240930xex31d2.htm Edgar Link pending
tela-20240930xex32d1.htm Edgar Link pending
tela-20240930xex32d2.htm Edgar Link pending
tela-20240930x10q_htm.xml Edgar Link completed
tela-20240930_cal.xml Edgar Link unprocessable
tela-20240930_def.xml Edgar Link unprocessable
tela-20240930_lab.xml Edgar Link unprocessable
tela-20240930_pre.xml Edgar Link unprocessable